| P2093 | author name string | Kenneth A Jacobson | |
| P2860 | cites work | Flexible modulation of agonist efficacy at the human A3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000 | Q21262008 |
| | 125I-4-(2-[7-amino-2-[2-furyl][1,2,4]triazolo[2,3-a][1,3,5] triazin-5-yl-amino]ethyl)phenol, a high affinity antagonist radioligand selective for the A2a adenosine receptor | Q24624185 |
| | Adenosine receptors as therapeutic targets | Q24632095 |
| | Adenosine receptors and asthma in humans | Q24644125 |
| | A physiological role of the adenosine A 3 receptor: Sustained cardioprotection | Q24650457 |
| | The A3 adenosine receptor agonist CP-532,903 [N6-(2,5-dichlorobenzyl)-3'-aminoadenosine-5'-N-methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel | Q24651378 |
| | Adenosine receptors: therapeutic aspects for inflammatory and immune diseases | Q24651475 |
| | The A(2A)-adenosine receptor: a GPCR with unique features? | Q24653743 |
| | The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist | Q24654563 |
| | BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy | Q28207909 |
| | International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors | Q28209239 |
| | Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage | Q28214799 |
| | Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study | Q28240363 |
| | The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance | Q28253272 |
| | Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpurines | Q28276510 |
| | Adenosine A1 and A3 receptors protect astrocytes from hypoxic damage | Q28291855 |
| | Inhibition of monoamine oxidase B by analogues of the adenosine A2A receptor antagonist (E)-8-(3-chlorostyryl)caffeine (CSC) | Q28294306 |
| | The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment | Q28297684 |
| | Use of the triazolotriazine [3H]ZM 241385 as a radioligand at recombinant human A2B adenosine receptors | Q28343854 |
| | Evaluation of homology modeling of G-protein-coupled receptors in light of the A(2A) adenosine receptor crystallographic structure. | Q30376612 |
| | Adenosine Receptors: The Contributions by John W. Daly. | Q30384658 |
| | Regulated catalysis of extracellular nucleotides by vascular CD39/ENTPD1 is required for liver regeneration | Q30435545 |
| | Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy | Q30438880 |
| | Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor | Q33931315 |
| | Purinergic receptors in gastrointestinal inflammation | Q34008598 |
| | Extracellular metabolism of ATP and other nucleotides | Q34101805 |
| | A3-adenosine receptors: design of selective ligands and therapeutic prospects | Q34204046 |
| | Repeated dosing with oral allosteric modulator of adenosine A1 receptor produces tolerance in rats with neuropathic pain | Q34314050 |
| | In vivo imaging of adenosine A2A receptors in rat and primate brain using [11C]SCH442416. | Q34368929 |
| | Progress in the pursuit of therapeutic adenosine receptor antagonists | Q34480029 |
| | Targeting adenosine A2A receptors in Parkinson's disease | Q34571644 |
| | Adenosine: trigger and mediator of cardioprotection | Q34713059 |
| | Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility | Q34734061 |
| | Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). | Q34756419 |
| | Recent improvements in the development of A(2B) adenosine receptor agonists | Q34774668 |
| | The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways. | Q34797617 |
| | Signalling from adenosine receptors to mitogen-activated protein kinases | Q35166514 |
| | Adenosine receptor agonists: from basic medicinal chemistry to clinical development | Q35602688 |
| | Anticonvulsant and antinociceptive actions of novel adenosine kinase inhibitors | Q36002941 |
| | Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs | Q36094581 |
| | Allosteric modulation of the adenosine family of receptors | Q36172721 |
| | Adenosine A3 receptor stimulation and cerebral ischemia | Q36185246 |
| | Functions of heteromeric association between adenosine and P2Y receptors. | Q36191603 |
| | Heterodimerization of g protein-coupled receptors: specificity and functional significance. | Q36234555 |
| | The cross-species A3 adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure | Q36317172 |
| | The A2b adenosine receptor protects against vascular injury | Q36393058 |
| | Advances in pharmacologic agents in imaging: new A2A receptor agonists | Q36416508 |
| | Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness | Q36690694 |
| | Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists. | Q36725267 |
| | Host A(2B) adenosine receptors promote carcinoma growth | Q36840284 |
| | Molecular modeling of a PAMAM-CGS21680 dendrimer bound to an A2A adenosine receptor homodimer. | Q36876553 |
| | Enhanced A3 adenosine receptor selectivity of multivalent nucleoside-dendrimer conjugates. | Q36970794 |
| | Selective A(3) adenosine receptor antagonists derived from nucleosides containing a bicyclo[3.1.0]hexane ring system | Q36996182 |
| | The A3 adenosine receptor: an enigmatic player in cell biology | Q37009175 |
| | Internalization and desensitization of adenosine receptors | Q37119883 |
| | The A3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats | Q37180330 |
| | Purinergic signalling and disorders of the central nervous system | Q37203929 |
| | Synthesis and characterization of [76Br]-labeled high-affinity A3 adenosine receptor ligands for positron emission tomography | Q37268033 |
| | Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists | Q40204712 |
| | Activation of the adenosine A3 receptor in RAW 264.7 cells inhibits lipopolysaccharide-stimulated tumor necrosis factor-alpha release by reducing calcium-dependent activation of nuclear factor-kappaB and extracellular signal-regulated kinase 1/2. | Q40368099 |
| | 18F-CPFPX PET identifies changes in cerebral A1 adenosine receptor density caused by glioma invasion. | Q40449962 |
| | The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition | Q40538226 |
| | Arrestin specificity for G protein-coupled receptors in human airway smooth muscle | Q40797346 |
| | N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects | Q40930252 |
| | Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8-cyclopentyl-1,3-dipropylxanthine (CPX) and 1,3-diallyl-8-cyclohexylxanthine (DAX). | Q41052360 |
| | Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors | Q42165593 |
| | Characterization of 8-(N-methylisopropyl)amino-N6-(5'-endohydroxy- endonorbornyl)-9-methyladenine (WRC-0571), a highly potent and selective, non-xanthine antagonist of A1 adenosine receptors. | Q42556447 |
| | The Quintiles Prize Lecture 2004. The identification of the adenosine A2B receptor as a novel therapeutic target in asthma | Q43261411 |
| | Modeling the adenosine receptors: comparison of the binding domains of A2A agonists and antagonists | Q44636374 |
| | Comparison of three different A1 adenosine receptor antagonists on infarct size and multiple cycle ischemic preconditioning in anesthetized dogs | Q44666472 |
| | Randomized, controlled dose-ranging study of the selective adenosine A2A receptor agonist binodenoson for pharmacological stress as an adjunct to myocardial perfusion imaging | Q44735739 |
| | Effect of a specific and selective A(2B) adenosine receptor antagonist on adenosine agonist AMP and allergen-induced airway responsiveness and cellular influx in a mouse model of asthma | Q44925341 |
| | Structure-activity relationships of adenosine A3 receptor ligands: new potential therapy for the treatment of glaucoma | Q44941156 |
| | New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine | Q44967992 |
| | Selective inactivation or reconstitution of adenosine A2A receptors in bone marrow cells reveals their significant contribution to the development of ischemic brain injury | Q45078353 |
| | Adenosine A2A receptor stimulation increases angiogenesis by down-regulating production of the antiangiogenic matrix protein thrombospondin 1. | Q45240162 |
| | ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. | Q45930388 |
| | The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment | Q46197378 |
| | A novel non-xanthine adenosine A1 receptor antagonist | Q46278603 |
| | A new orally bioavailable dual adenosine A2B/A3 receptor antagonist with therapeutic potential. | Q46474552 |
| | BG-9928 (Biogen Idec). | Q46723486 |
| | Toward multivalent signaling across G protein-coupled receptors from poly(amidoamine) dendrimers | Q46821943 |
| | Preparation and first evaluation of [(18)F]FE@SUPPY: a new PET tracer for the adenosine A(3) receptor. | Q46833478 |
| | Protective roles of adenosine A1, A2A, and A3 receptors in skeletal muscle ischemia and reperfusion injury | Q46962262 |
| | The two-state dimer receptor model: a general model for receptor dimers | Q46963124 |
| | Moderate cerebral venous congestion induces rapid cerebral protection via adenosine A1 receptor activation | Q48386801 |
| | Activation of adenosine A3 receptors reduces ischemic brain injury in rodents. | Q48406066 |
| | ADOA3R as a therapeutic target in experimental colitis: proof by validated high-density oligonucleotide microarray analysis | Q50718849 |
| | Hypoglycemic and hypotensive effects of 6-cyclohexyl-2′-O-methyl-adenosine, an adenosine A1 receptor agonist, in spontaneously hypertensive rat complicated with hyperglycemia | Q52159834 |
| | Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans | Q53469916 |
| | Cross-talk between G(s)- and G(q)-coupled pathways in regulation of interleukin-4 by A(2B) adenosine receptors in human mast cells. | Q53622261 |
| | Overexpression of A3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of nuclear factor-kappaB in mediating receptor level. | Q54562922 |
| | Cardiovascular and antilipolytic effects of the adenosine agonist GR79236 | Q70941789 |
| | 11C-labeled KF18446: a potential central nervous system adenosine A2a receptor ligand | Q73477592 |
| | Adenosine A2A receptor occupancy stimulates collagen expression by hepatic stellate cells via pathways involving protein kinase A, Src, and extracellular signal-regulated kinases 1/2 signaling cascade or p38 mitogen-activated protein kinase signalin | Q81302870 |
| | A1 adenosine receptor agonists and their potential therapeutic applications | Q82623922 |
| P433 | issue | 193 | |
| P304 | page(s) | 1-24 | |
| P577 | publication date | 2009-01-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Handbook of experimental pharmacology | Q26841924 |
| P1476 | title | Introduction to adenosine receptors as therapeutic targets | |